View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Liver/Biliary Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
November 28, 2022
2 min read
Save

Palliative care beneficial for patients with end-stage liver disease

Palliative care beneficial for patients with end-stage liver disease

CHARLOTTE, N.C. — Early palliative care referral would benefit patients with end-stage liver disease, resulting in fewer hospitalizations and more health care proxy assignments and code status changes, according to a presenter here.

SPONSORED CONTENT
November 21, 2022
2 min read
Save

Hyperferritinemia may indicate progression of liver disease, poor prognosis in MAFLD

Hyperferritinemia may indicate progression of liver disease, poor prognosis in MAFLD

CHARLOTTE, N.C. — Elevated ferritin correlated with an increased prevalence of cirrhosis — but not congestive heart failure — in patients with metabolic dysfunction-associated fatty liver disease, according to a presenter here.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
November 21, 2022
2 min read
Save

Terlipressin reduced need for renal replacement therapy 1 year after liver transplant

Terlipressin reduced need for renal replacement therapy 1 year after liver transplant

CHARLOTTE, N.C. — A subgroup analysis of liver transplant patients with hepatorenal syndrome type 1 demonstrated that terlipressin decreased the need for renal replacement therapy up to 12 months following transplantation.

SPONSORED CONTENT
November 18, 2022
2 min read
Save

Recent injection drug use linked to HCV reinfection after DAA treatment

Recent injection drug use linked to HCV reinfection after DAA treatment

WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.

SPONSORED CONTENT
November 18, 2022
1 min read
Save

Global NAFLD prevalence rose 50% over 20 years, with hotspots in North Africa, Middle East

Global NAFLD prevalence rose 50% over 20 years, with hotspots in North Africa, Middle East

CHARLOTTE, N.C. —Nonalcoholic fatty liver disease prevalence rose more than 50% globally from 1990 to 2019, with African and Middle Eastern regions identified as hotspots, according to data presented at ACG Annual Scientific Meeting.

SPONSORED CONTENT
November 17, 2022
2 min read
Save

HCV care must ‘move away from the ivory tower’ to achieve elimination

HCV care must ‘move away from the ivory tower’ to achieve elimination

WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.

SPONSORED CONTENT
November 16, 2022
2 min read
Save

Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050

Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050

WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.

SPONSORED CONTENT
November 15, 2022
2 min read
Save

ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV

ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV

WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.

SPONSORED CONTENT
November 12, 2022
2 min read
Save

Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks

Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks

WASHINGTON — Bulevirtide monotherapy was safe and effective at 72 weeks for patients with hepatitis D virus-related compensated cirrhosis, with virological and clinical responses increasing over time, according to data presented here.

SPONSORED CONTENT
November 11, 2022
4 min watch
Save

VIDEO: Women with NASH-cirrhosis at higher risk for polypharmacy to manage chronic pain

VIDEO: Women with NASH-cirrhosis at higher risk for polypharmacy to manage chronic pain

WASHINGTON — In a Healio video exclusive, Leen Al-Sayyed, MD, gastroenterology and transplant hepatology fellow at St. Louis University, reported women with nonalcoholic steatohepatitis-cirrhosis had an increased prevalence for polypharmacy.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails